Display Settings:

Format

Send to:

Choose Destination
    Antimicrob Agents Chemother. 2010 Apr;54(4):1616-8. Epub 2010 Jan 19.

    Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.

    Source

    University of Pavia, Department of Genetics and Microbiology, Via Ferrata 1, 27100 Pavia, Italy. m.pasca@ipvgen.unipv.it

    Abstract

    The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.

    PMID:
    20086151
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2849388
    Free PMC Article

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk